Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

M.D. Anderson Cancer Center

Status: Enrolling

Conditions: Resectable Sarcoma; Metastatic Sarcoma; Recurrent Sarcoma

Treatments: Drug: Ifosfamide; Drug: Doxorubicin; Procedure: Therapeutic Conventional Surgery; Biological: Ganitumab; Drug: Pazopanib; Device: Drug Delivery Microdevice; Drug: Temsirolimus; Drug: Temozolomide; Drug: Doxorubicin Hydrochloride; Drug: Irinotecan; Drug: Everolimus; Drug: Polyethylene Glycol; Drug: Vincristine

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT04199026

R01CA180279 (U.S. NIH Grant/Contract)

2019-0171 (Other Identifier)

NCI-2019-05820 (Registry Identifier)

Details and patient eligibility

About

This early phase I trial studies the side effects of implanting and removing a microdevice in patients with sarcomas that have spread to other places in the body (metastatic) or have come back (recurrent). Microdevices are rice-sized devices that are implanted into tumor tissue and are loaded with 10 different drugs that are delivered at very small doses, or "microdoses," which may only affect a very small, local area inside the tumor. The purpose of this study is to determine which drugs delivered in the microdevice affect tumor tissue in patients with sarcomas.

Full description

PRIMARY OBJECTIVES:

I. Assess the safety of drug delivery microdevice (microdevice) placement and removal in subjects undergoing resection of sarcoma.

II. Determine the technical feasibility of microdevice placement and removal with intact surrounding tissue in subjects undergoing resection of a sarcoma.

SECONDARY OBJECTIVE:

I. Use the intratumoral cellular response to evaluate individual agents and/or drug combinations released from the microdevice reservoirs to assess the relative drug efficacy across all individual agents or drug combinations tested using the microdevice technology.

EXPLORATORY OBJECTIVES:

I. Evaluate the microdevice performance for its capacity to predict Response Evaluation Criteria in Solid Tumors (RECIST) response in the subset of patients that receive systemic chemotherapies as part of their standard-of-care or clinical trial treatments. II. Determine genomic, transcriptomic, and proteomic predictive biomarkers from resected specimens that correlate with local (i.e. microdevice-based) and systemic drug response. III. Determine, at a single-cell level, proteomic traits associated with chemosensitivity versus (vs.) resistance using mathematical notions of network robustness and fragility.

OUTLINE:

Patients undergo percutaneous implantation of up to 3 drug delivery microdevices up to 2 days before standard of care surgery. Patients receive doxorubicin hydrochloride, ifosfamide, vincristine, irinotecan, temozolomide, pazopanib, everolimus, polyethylene glycol, ganitumab, and temsirolimus via the microdevice in the absence of unacceptable toxicity. At the time of surgery 2 days later, patients have the drug delivery microdevice(s) removed. Conditions Conditions: Metastatic Sarcoma Recurrent Sarcoma

Enrollment: 20 estimated patients

Sex: All

Ages: 10+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion:

• Patients with a biopsy-confirmed recurrent or metastatic sarcoma for which surgery is indicated as a standard of care.
• 10 years of age or older
• Documented, signed, dated informed consent to participate in the microdevice study
• Eastern Cooperative Oncology Group (ECOG) performance status of =< 2

Exclusion:

• Subjects who do not wish to undergo surgical resection, or those who are high-risk or not candidates for surgical resection
• Age < 10 years old
• Women of childbearing potential without a negative pregnancy test; or women who are lactating
• Allergies or prior adverse drug reactions to any of the drugs loaded within the microdevice.

Trial design

Primary purpose: Device Feasibility

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

20 participants in 1 patient group

Device Feasibility (microdevice, surgery)

Experimental group

Description:

Patients undergo percutaneous implantation of up to 3 drug delivery microdevices up to 2 days before standard of care surgery. Patients receive doxorubicin hydrochloride, ifosfamide, vincristine, irinotecan, temozolomide, pazopanib, everolimus, polyethylene glycol, ganitumab, and temsirolimus via the microdevice in the absence of unacceptable toxicity. At the time of surgery 2 days later, patients have the drug delivery microdevice(s) removed.

Treatment:

Drug: Vincristine

Drug: Polyethylene Glycol

Drug: Irinotecan

Drug: Everolimus

Drug: Temozolomide

Drug: Doxorubicin Hydrochloride

Drug: Temsirolimus

Device: Drug Delivery Microdevice

Drug: Pazopanib

Procedure: Therapeutic Conventional Surgery

Biological: Ganitumab

Drug: Doxorubicin

Drug: Ifosfamide